Skip to main navigation Skip to search Skip to main content

A Self-Propagating c-Met–SOX2 Axis Drives Cancer-Derived IgG Signaling That Promotes Lung Cancer Cell Stemness

  • Xinmei Huang
  • , Shenghua Zhang
  • , Jingshu Tang
  • , Tian Tian
  • , Yilin Pan
  • , Lina Wu
  • , Jingxuan Zhang
  • , Yang Liu
  • , Jing Huang
  • , Hui Dai
  • , Weiyan Xu
  • , Youhui Zhang
  • , Jinfeng Chen
  • , Mengshu Cao
  • , Liang Zhang*
  • , Xiaoyan Qiu*
  • *Corresponding author for this work

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

Abstract

Elevated IgG expression in cancer cells has been implicated in exacerbated malignancy and poor clinical prognosis. Accumulating evidence indicates that a nonconventional sialylation modification is critical for the function of cancer-derived IgG, indicating the need for a better understanding of the regulatory mechanisms that control the expression and function of sialylated cancer IgG (SIA-cIgG). Here, we conducted genome-wide CRISPR activation screening and identified OCT4 and SOX2 as the key factors that promote SIA-cIgG expression. Functional investigation revealed that SIA-cIgG reciprocally stimulated SOX2 by activating the c-Met/Akt/Erk signaling axis, constituting a self-propagating loop of SIA-cIgG/c-Met/SOX2/SIA-cIgG signaling. This signaling loop was highly active in stem-like cells from many epithelial cancers and was crucial for cancer stemness in vitro and in vivo. Notably, the monoclonal antibody RP215, which specifically recognizes the Asn162 sialylation-related epitope on SIA-cIgG, effectively blocked the SIA-cIgG-driven signaling loop. Furthermore, RP215 significantly inhibited lung cancer cell stemness and tumor growth in a patient-derived xenograft model. In conclusion, these findings revealed a self-propagating c-Met/SOX2/SIA-cIgG signaling loop that promotes cancer stemness, identifying novel therapeutic strategies for cancer treatment. © 2023 American Association for Cancer Research.

Original languageEnglish
Pages (from-to)1866-1882
JournalCancer Research
Volume83
Issue number11
Online published29 Mar 2023
DOIs
Publication statusPublished - 1 Jun 2023

Bibliographical note

Information for this record is supplemented by the author(s) concerned.

Funding

The authors thank the Annoroad Gene Company (Beijing, China) for supporting the next-generation sequencing (NGS). They also thank Xiajuan Zou, Peking University Health Science Center (Beijing, China), for assistance in LC/MS-MS analysis. This work was supported by the National Natural Science Foundation of China (82030044, 81971465, 91642206), Shenzhen Science and Technology Innovation Commission (JCYJ20180507181659781, JCYJ20210324133812034), The Research Grant Council of Hong Kong (11103318, 11104422, and 11102322), Shenzhen-Hong Kong Science, and Technology Innovation Cooperation Zone Shenzhen Park Project (HZQB-KCZYZ-2021017), and The Tung Foundation Biomedical Sciences Centre (9609301).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Keywords

  • Cancer-derived IgG
  • sialylated cancer IgG (SIA-cIgG)
  • cancer stem cells (CSCs)
  • c-Met
  • SOX2

RGC Funding Information

  • RGC-funded

Fingerprint

Dive into the research topics of 'A Self-Propagating c-Met–SOX2 Axis Drives Cancer-Derived IgG Signaling That Promotes Lung Cancer Cell Stemness'. Together they form a unique fingerprint.

Cite this